CFDE Data Portal | Search HECTD2-AS1

	Label	Description
	HECTD2-AS1 associations Collection (Entity type)	Associations for HECTD2-AS1_associations
	HECTD2-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	HECTD2-AS1 Gene (Entity type)	ENSG00000289228 - HECTD2 antisense RNA 1
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE234647 1 V 3 REGORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE115395 2 V 4 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 3 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE166315 1 V 0 DOCETAXEL MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE135352 0 V 1 NAPABUCASIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

HECTD2-AS1 associations

Associations for HECTD2-AS1_associations

HECTD2-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

HECTD2-AS1

ENSG00000289228 - HECTD2 antisense RNA 1

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE199107 tryptophan 6 v 7 human up

A Gene Set from LINCS

GSE234647 1 V 3 REGORAFENIB HUMAN UP

A Gene Set from LINCS

GSE115395 2 V 4 ENZALUTAMIDE HUMAN DN

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 3 v 11 human dn

A Gene Set from LINCS

GSE166315 1 V 0 DOCETAXEL MOUSE UP

A Gene Set from LINCS

GSE135352 0 V 1 NAPABUCASIN HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.